This work describes validation of exoribonuclease XRN1 as a selective oncology target and development of a suite of assays to support XRN1 drug development, including a human crystal structure of XRN1 bound to adenosine-3’,5’-bisphosphate (pAp).
- Gordon J. Lockbaum
- Maureen M. Lynes
- P. Ann Boriack-Sjodin
